摘要
钠-葡萄糖共转运蛋白-2(SGLT-2)抑制剂最初是用于治疗2型糖尿病的降糖药物,但临床试验证实,SGLT-2抑制剂除降糖作用外,还具有额外的心肾获益,目前已被指南作为“四驾马车”之一推荐用于心衰患者及糖尿病合并慢性肾脏病患者。目前,SGLT-2抑制剂对于心肾保护的详细机制尚不十分明确,可能包括降压、改善内皮功能及心脏和肾脏血流动力学、减少炎症和氧化应激等机制。本文就SGLT-2抑制剂在心肾保护中的临床证据及可能机制作一综述。
The sodium glucose cotransporter-2(SGLT-2)inhibitor was initially used as a hypoglycemic drug in patients with type 2 diabetes mellitus(T2DM).However,clinical trials have confirmed that SGLT-2 inhibitor has additional cardio-renal benefits in addition to its hypoglycemic effect and has been recommended by the guidelines as one of the cornerstones for patients with heart failure and T2DM with chronic kidney disease.At present,the precise mechanisms of cardio-renal protection of SGLT-2 inhibitor are not very clear,which may include lowering the blood pressure,improving the endothelial function and cardio-renal hemodynamics,inhibiting the inflammatory reaction and oxidative stress etc.This article reviews the clinical evidence and possible mechanisms of SGLT-2 inhibitor in cardio-renal protection.
作者
谢林峰
罗素新
黄毕
Xie Linfeng;Luo Suxin;Huang Bi(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400700,China)
基金
白求恩公益基金会项目(J202103E006)
“重庆英才计划”项目(CQYC20210303368)
重庆医科大学未来医学青年创新团队发展支持计划项目(W0184)。
